International Stem Cell (ISCO) Cost of Revenue (2010 - 2026)

International Stem Cell (ISCO) has reported Cost of Revenue for 17 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 31.28% year-over-year to $1.2 million in Q2 2026; TTM through Jun 2026 was $4.3 million, a 9.66% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 7.15% from the prior year.
• Cost of Revenue was $1.2 million for Q2 2026 at International Stem Cell, up from $1.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $1.2 million in Q2 2026 and troughed at $690000.0 in Q3 2022.
• A 5-year average of $909647.1 and a median of $913000.0 in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 54.56% in 2022 and declined 24.03% in 2023, its largest moves.
• Over 5 years, Cost of Revenue stood at $1.1 million in 2022, then slipped by 24.03% to $863000.0 in 2023, then grew by 14.72% to $990000.0 in 2024, then rose by 7.68% to $1.1 million in 2025, then increased by 14.17% to $1.2 million in 2026.
• The last three Cost of Revenue figures came in at $1.2 million (Q2 2026), $1.1 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.